 |
14 Products |  |
223 Diseases | | 14 Products |
|
9 Trials |  |
2094 News |  |
| «12...567891011121314151617 |
- ||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Trial completion: Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients (clinicaltrials.gov) - Feb 12, 2014
P3, N=498, Completed, Sponsor: Mundipharma Research Limited
Active, not recruiting --> Completed
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: NVA237 BID Versus Placebo Twelve-week Efficacy Study (clinicaltrials.gov) - Feb 6, 2014
P3, N=432, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- |||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment open: A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD (clinicaltrials.gov) - Feb 4, 2014
P3, N=1530, Recruiting, Sponsor: Mundipharma Research Limited
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment closed: Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jan 26, 2014
P3, N=763, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- micronized fenofibrate / Generic mfg., rosiglitazone / Generic mfg., fenofibrate / Generic mfg.
Trial termination: Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) (clinicaltrials.gov) - Jan 23, 2014
P4, N=41, Terminated, Sponsor: Ahmad Slim
Recruiting --> Active, not recruiting Completed --> Terminated; Slow recruitment and increase in deployment overseas limiting follow up
- micronized fenofibrate / Generic mfg., rosiglitazone / Generic mfg., fenofibrate / Generic mfg.
Enrollment change: Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) (clinicaltrials.gov) - Jan 23, 2014
P4, N=41, Terminated, Sponsor: Ahmad Slim
Completed --> Terminated; Slow recruitment and increase in deployment overseas limiting follow up N=80 --> 41
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: NVA237 Versus Placebo 12-week Efficacy Study (clinicaltrials.gov) - Jan 13, 2014
P3, N=440, Completed, Sponsor: Novartis Pharmaceuticals
N=80 --> 41 Active, not recruiting --> Completed
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial suspension: Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. (clinicaltrials.gov) - Jan 12, 2014
P3, N=340, Suspended, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Suspended
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial initiation date: Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. (clinicaltrials.gov) - Jan 12, 2014
P3, N=340, Suspended, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Suspended Initiation date: Oct 2013 --> Apr 2014
- | alpha-1-antitrypsin inhalation (VR179) / Vectura, Grifols
Enrollment change: Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Nov 25, 2013
P2, N=41, Completed, Sponsor: Grifols Therapeutics Inc.
Initiation date: Oct 2013 --> Apr 2014 N=30 --> 41
- | alpha-1-antitrypsin inhalation (VR179) / Vectura, Grifols
Trial completion: Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Nov 25, 2013
P2, N=41, Completed, Sponsor: Grifols Therapeutics Inc.
N=30 --> 41 Active, not recruiting --> Completed
- ||||||| VR506 / Hikma, Vectura
Trial completion: Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma (clinicaltrials.gov) - Nov 5, 2013
P2/3, N=197, Completed, Sponsor: Vectura Limited
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment open: Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Sep 23, 2013
P4, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
New P3 trial: A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD (clinicaltrials.gov) - Sep 17, 2013
P3, N=1530, Recruiting, Sponsor: Mundipharma Research Limited
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial withdrawal: GLOW8: Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (clinicaltrials.gov) - Aug 25, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment change: GLOW8: Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (clinicaltrials.gov) - Aug 25, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn N=1120 --> 0
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment change: GLOW5: Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Aug 25, 2013
P3, N=657, Completed, Sponsor: Novartis Pharmaceuticals
N=1120 --> 0 N=980 --> 657
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
Enrollment change: GLOW6: Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Aug 20, 2013
P3, N=445, Completed, Sponsor: Novartis Pharmaceuticals
N=980 --> 657 N=671 --> 445
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P4 trial: Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Aug 12, 2013
P4, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jul 30, 2013
P3, N=458, Completed, Sponsor: Novartis Pharmaceuticals
N=671 --> 445 Recruiting --> Completed
- ||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Trial completion: A Study Assessing Patient Handling of Flutiform® Breath-Actuated Inhaler (BAI) and Flutiform® Pressurised Metered Dose Inhaler (pMDI) (clinicaltrials.gov) - Jun 26, 2013
P=N/A, N=332, Completed, Sponsor: Mundipharma Research Limited
Recruiting --> Completed Recruiting --> Completed
- ||||||| VR506 / Hikma, Vectura
Trial completion: Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma (clinicaltrials.gov) - May 16, 2013
P2/3, N=374, Completed, Sponsor: Vectura Limited
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. (clinicaltrials.gov) - Apr 21, 2013
P3, N=340, Suspended, Sponsor: Novartis Pharmaceuticals
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
Trial completion: GLOW6: Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Mar 24, 2013
P3, N=445, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- Triglide (fenofibrate) / Vectura, Shionogi
Biomarker, Enrollment open: Lipid Biomarkers for Diabetic Heart Disease (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=104, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: GLOW5: Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Mar 13, 2013
P3, N=657, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial initiation date: GLOW8: Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (clinicaltrials.gov) - Feb 10, 2013
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Initiation date: Jan 2013 --> Apr 2013
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: GLOW8: Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (clinicaltrials.gov) - Dec 26, 2012
P3, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment change: GLOW4: Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients (clinicaltrials.gov) - Dec 11, 2012
P3, N=211, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2013 --> Apr 2013 N=160 --> 211
- |||||||||| VR506 / Hikma, Vectura
New P2/3 trial: Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma (clinicaltrials.gov) - Oct 30, 2012
P2/3, N=197, Completed, Sponsor: Vectura Limited
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: NVA237 BID Versus Placebo Twelve-week Efficacy Study (clinicaltrials.gov) - Oct 24, 2012
P3, N=432, Completed, Sponsor: Novartis Pharmaceuticals
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: NVA237 Versus Placebo 12-week Efficacy Study (clinicaltrials.gov) - Oct 16, 2012
P3, N=440, Completed, Sponsor: Novartis Pharmaceuticals
- | apomorphine inhalational (VR 040) / Vectura, Kyowa Kirin
New P2a trial: VR040/2/003: Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease (clinicaltrials.gov) - Sep 24, 2012
P2a, N=47, Completed, Sponsor: South Glasgow University Hospitals NHS Trust
- | alpha-1-antitrypsin inhalation (VR179) / Vectura, Grifols
New P2 trial: Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis (clinicaltrials.gov) - Sep 11, 2012
P2, N=41, Completed, Sponsor: Grifols Therapeutics Inc.
- | apomorphine inhalational (VR 040) / Vectura, Kyowa Kirin
New P2 trial: Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease (clinicaltrials.gov) - Sep 9, 2012
P2, N=29, Completed, Sponsor: South Glasgow University Hospitals NHS Trust
- ||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment change: Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma (clinicaltrials.gov) - Aug 8, 2012
P3, N=1667, Completed, Sponsor: Mundipharma Research Limited
N=160 --> 211 N=508 --> 1667
- | Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Enrollment change: Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma (clinicaltrials.gov) - Aug 7, 2012
P2, N=46, Completed, Sponsor: Mundipharma Research Limited
N=508 --> 1667 N=60 --> 46
- | Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Trial completion: Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma (clinicaltrials.gov) - Aug 7, 2012
P2, N=46, Completed, Sponsor: Mundipharma Research Limited
N=60 --> 46 Recruiting --> Completed
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: GLOW5: Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Jun 5, 2012
P3, N=657, Completed, Sponsor: Novartis Pharmaceuticals
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P1 trial: Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment (clinicaltrials.gov) - Jun 5, 2012
P1, N=48, Completed, Sponsor: Novartis Pharmaceuticals
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
New P3 trial: GLOW6: Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - May 21, 2012
P3, N=445, Completed, Sponsor: Novartis Pharmaceuticals
- ||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: GLOW4: Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients (clinicaltrials.gov) - Apr 16, 2012
P3, N=211, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Mar 27, 2012
P3, N=458, Completed, Sponsor: Novartis Pharmaceuticals
- ||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment change: GLOW 1: A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo (clinicaltrials.gov) - Mar 14, 2012
P3, N=1324, Completed, Sponsor: Novartis
Active, not recruiting --> Completed N=800 --> 1324
- ||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Trial completion: Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma (clinicaltrials.gov) - Feb 28, 2012
P3, N=261, Completed, Sponsor: Mundipharma Research Limited
N=800 --> 1324 Recruiting --> Completed
- apomorphine inhalational (VR 040) / Vectura, Kyowa Kirin
New P2 trial, Metastases: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalating Study Investigating the Efficacy and Safety of VR040 in the Treatment of Unpredictable “Off” or End-of-Dose “Wearing Off” Episodes in Patients With Advanced Idiopathic Parkinson’s Disease (EUDRACT) - Jan 22, 2012
P2, N=24, Ongoing, Sponsor: Vectura Group plc
- |||||||||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P3 trial: Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Jan 18, 2012
P3, N=763, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- |||||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
New P3 trial: Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients (clinicaltrials.gov) - Jan 16, 2012
P3, N=498, Completed, Sponsor: Mundipharma Research Limited
- |||||||||| VR506 / Hikma, Vectura
New P2/3 trial: Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma (clinicaltrials.gov) - Nov 14, 2011
P2/3, N=374, Completed, Sponsor: Vectura Limited